Irinotecan Hydrochloride Trihydrate — Drug Intelligence | 58 EU Trials

Filter these 58 trials by condition, phase, country and more.

Open in Search →

58 Registered trials

34 Recruiting

16 Completed trials

40 Sponsors

21 Countries

Phase III

Phase II

Phase III: 20 Phase II/III: 3 Phase II: 27 Phase I/II: 4 Phase III/IV: 1 Phase I (Other): 1 Phase I (FiH): 2

Oversight events:

1 serious breach 5 temporary halts across 2 trials

View oversight register →

Indications tested

Colorectal cancer 4 Rectal cancer 3 Colorectal cancer metastatic 3 Neuroblastoma 2 Cholangiocarcinoma 1 Ewing's sarcoma 1 Rectal adenocarcinoma 1 Desmoplastic small round cell tumour 1 Pancreatic carcinoma 1 Rectal cancer recurrent 1

Sponsors using this IMP

Catharina Ziekenhuis Stichting 6 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 5 AstraZeneca AB 3 IRCCS Istituto Nazionale Tumori Fondazione Pascale 3 Amsterdam UMC 2 Bristol-Myers Squibb Services Unlimited Company 2 Centre Hospitalier Universitaire De Dijon 2 Institut Gustave Roussy 2 Pfizer Inc. 2 1globe Health Institute LLC 1 Amgen Inc. 1 Amsterdam UMC Stichting 1

All trials — page 3

58 total

Induction chemotherapy for locally advanced rectal cancer. Ended

2023-509758-74-00 Phase II 1 country Catharina Ziekenhuis Stichting
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Phase III 13 countries Pfizer Inc.
Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastases. - Th… Ended

2024-515525-28-00 Phase II/III 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment f… Ended

2024-514705-62-00 Phase III 1 country Centre Hospitalier Universitaire De Bordeaux
Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma - a phase… Ended

2023-509044-96-00 Phase II 2 countries Region Skane
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE… Ended

2024-516260-29-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Phase II 5 countries Gilead Sciences Inc.
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended

2024-511975-14-00 Phase I/II 5 countries Pfizer Inc.
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended

2023-503956-29-00 Phase III 12 countries Bristol-Myers Squibb Services Unlimited Company
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 Phase III 3 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Showing 49–58 of 58 trials

← All drugs A–Z